Preservation of Epstein-Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer.
Epstein-Barr virus
gastric cancer
metastases
microsatellite instability
mismatch repair
molecular subtype
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
08
10
2019
revised:
17
12
2019
accepted:
02
01
2020
pubmed:
4
1
2020
medline:
27
2
2021
entrez:
4
1
2020
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV) in-situ hybridisation and mismatch repair (MMR) protein immunohistochemistry identifies two subgroups of gastric cancer (GC) with high immunogenicity and likelihood for response to immune check-point inhibition. As tumour biology may change during the metastatic course, which can negatively influence the success of therapeutic decisions made on primary tissue, we investigated the consistency of GC EBV and MMR status within primary tumours and metastases. We investigated a cohort of 415 primary resected GC, including 111 cases with corresponding distant metastases and 297 cases with lymph node metastases. Tumours were analysed by EBV in-situ hybridisation and MLH1, PMS2, MSH2 and MSH6 immunohistochemistry using tissue microarray technique. Primary tumours were grouped as EBV-positive MMR-proficient, EBV-negative MMR-deficient and EBV-negative MMR-proficient. Eleven of 415 (2.7%) of primary tumours were EBV-positive MMR-proficient, whereas 49 of 415 (11.8%) of tumours were EBV-negative MMR-deficient. EBV and MMR protein status showed full concordance with that of the primary tumours. MMR-deficient tumours were of lower pT-category (P < 0.001), had fewer lymph node metastases [24 of 49 (49%) versus 273 of 361 (75.6%) cases; P < 0.001] and a lower rate of distant metastases [six of 49 (12.2%) versus 105 of 366 (28.7%) cases; P = 0.015]. We demonstrate a strong correlation of EBV and MMR status between primary tumours, lymph node and distant metastases in a large series of primary resected GC. The cases showed the expected frequency of EBV-positive MMR-deficient and EBV-negative MMR-proficient tumours. We conclude that tissue testing for molecular subtyping for therapeutic decision-making can be reliably performed on primary tumours and metastases in GC.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
740-747Subventions
Organisme : Swiss Cancer League
ID : KFS-3700-08-2015
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Fitzmaurice C, Dicker D, Pain A et al. The global burden of cancer 2013. JAMA Oncol. 2015; 1; 505-527.
Liu X, Meltzer SJ. Gastric cancer in the era of precision medicine. Cell. Mol. Gastroenterol. Hepatol. 2017; 3; 348-358.
Svensson MC, Borg D, Zhang C et al. Expression of PD-L1 and PD-1 in chemoradiotherapy-naive esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival. Front. Oncol. 2019; 9; 136.
Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015; 136; E359-E386.
Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513; 202-209.
Chivu-Economescu M, Matei L, Necula LG et al. New therapeutic options opened by the molecular classification of gastric cancer. World J. Gastroenterol. 2018; 24; 1942-1961.
Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 2015; 21; 449-456.
Birkman EM, Mansuri N, Kurki S et al. Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics. Virchows Arch. 2018; 472; 369-382.
Diaz Del Arco C, Estrada Munoz L, Molina Roldan E et al. Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival. Virchows Arch. 2018; 473; 687-695.
Kim HS, Shin SJ, Beom SH et al. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget 2016; 7; 44608-44620.
Hewitt LC, Inam IZ, Saito Y et al. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: a large multi-centre study. Eur. J. Cancer 2018; 94; 104-114.
Chenard-Poirier M, Smyth EC. Immune checkpoint inhibitors in the treatment of gastroesophageal cancer. Drugs 2019; 79; 1-10.
Akyala AI, Verhaar AP, Peppelenbosch MP. Immune checkpoint inhibition in gastric cancer: a systematic review. J. Cell. Immunother. 2018; 4; 49-55.
Zlobec I, Koelzer VH, Dawson H, Perren A, Lugli A. Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J. Transl. Med. 2013; 11; 104.
Blaser N. Construction of a ngTMA of gastric adenocarcinoma and corresponding metastasis. Master of Medicine thesis, University of Bern, 2016.
Huang SC, Ng KF, Yeh TS et al. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases. Int. J. Cancer 2019; 145; 3218-3230.
Naseem M, Barzi A, Brezden-Masley C et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat. Rev. 2018; 66; 15-22.
Setia N, Agoston AT, Han HS et al. A protein and mRNA expression-based classification of gastric cancer. Mod. Pathol. 2016; 29; 772-784.
Kawazoe A, Shitara K, Kuboki Y et al. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer 2019; 22; 69-76.
Smyth EC, Wotherspoon A, Peckitt C et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3; 1197-1203.
Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355; 11-20.
Al-Batran S-E, Homann N, Pauligk C et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393; 1948-1957.